Review of medications being tested to treat cannabis use disorder
Among drugs tested for cannabis use disorder, those acting on the endocannabinoid system, particularly CB1 receptor agonists like nabilone, show the most promise for managing withdrawal, cravings, and relapse.
Quick Facts
What This Study Found
This review of randomized placebo-controlled trials found that CB1 receptor agonists (such as nabilone) showed the most promise for treating cannabis use disorder, while serotonergic, GABAergic, and other compound classes had more limited or mixed evidence.
Key Numbers
The review covered compounds including nabilone (CB1 agonist), bupropion (serotonergic), zolpidem (GABAergic), and others across multiple RCTs. CUD rates are increasing with cannabis legalization worldwide.
How They Did This
Narrative review evaluating evidence from randomized, placebo-controlled trials of pharmacotherapies for cannabis use disorder, organized by compound target and outcome (withdrawal symptoms, craving, relapse/use).
Why This Research Matters
There is currently no FDA-approved medication for cannabis use disorder, even as CUD rates rise with legalization. Identifying which medication classes work best could lead to effective treatments.
The Bigger Picture
The finding that endocannabinoid-system drugs work best mirrors the approach used for other substance use disorders, where agonist therapies (like methadone for opioids or nicotine replacement for tobacco) have proven most effective.
What This Study Doesn't Tell Us
Narrative rather than systematic review. Most trials have small sample sizes. Many compounds studied in limited populations. Females, certain racial/ethnic groups, and different age groups may respond differently.
Questions This Raises
- ?Will any of these medications reach FDA approval for CUD?
- ?How should treatment be tailored for populations that experience CUD differently?
Trust & Context
- Key Stat:
- CB1 agonists most promising for CUD
- Evidence Grade:
- Narrative review of RCTs provides organized evidence summary, but is not systematic and individual trials are often small.
- Study Age:
- 2024 narrative review of clinical trial evidence
- Original Title:
- Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action.
- Published In:
- Drugs, 84(11), 1395-1417 (2024)
- Authors:
- Alayoubi, Myra(3), Henry, Brittany A, Cahill, Catherine M(3), Cooper, Ziva D
- Database ID:
- RTHC-05073
Evidence Hierarchy
Frequently Asked Questions
Is there an approved medication for cannabis use disorder?
No. As of this review, no medication has been approved specifically for cannabis use disorder, though several are being tested in clinical trials.
What type of medication showed the most promise?
Drugs acting on the endocannabinoid system, particularly CB1 receptor agonists like nabilone, showed the most consistent evidence for reducing withdrawal symptoms, cravings, and cannabis use.
Read More on RethinkTHC
- 30-days-without-weed
- 420-sober-survival-guide
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- CBT-cannabis-recovery
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-relapse-cycle-pattern
- cannabis-use-disorder-test
- cold-turkey-vs-taper-quit-weed
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- hobbies-after-quitting-weed
- how-to-quit-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- journaling-weed-withdrawal
- leaving-stoner-culture-identity
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-face-changes-skin
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- should-i-quit-weed
- signs-of-cannabis-use-disorder
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-05073APA
Alayoubi, Myra; Henry, Brittany A; Cahill, Catherine M; Cooper, Ziva D. (2024). Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action.. Drugs, 84(11), 1395-1417. https://doi.org/10.1007/s40265-024-02098-1
MLA
Alayoubi, Myra, et al. "Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action.." Drugs, 2024. https://doi.org/10.1007/s40265-024-02098-1
RethinkTHC
RethinkTHC Research Database. "Exploring Novel Pharmacotherapy Candidates for Cannabis Use ..." RTHC-05073. Retrieved from https://rethinkthc.com/research/alayoubi-2024-exploring-novel-pharmacotherapy-candidates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.